APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antimicrobial Peptides

Antimicrobial peptides (AMPs), also called host defense peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous cells. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Antimicrobial peptides (AMPs), also called host defense peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous cells. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.

Selected research

Market Outlook & Growth Opportunities

Global Antimicrobial Peptides Market Outlook and Growth Opportunities 2026

1 January 2026193 pages

Choose your research edition.

Industry ResearchAntimicrobial Peptides Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Antimicrobial Peptides Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Antimicrobial Peptides Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antimicrobial Peptides Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Antimicrobial Peptides Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Antimicrobial peptides (AMPs), also called host defense peptides (HDPs) are part of the innate immune response found among all classes of life. Fundamental differences exist between prokaryotic and eukaryotic cells that may represent targets for antimicrobial peptides. These peptides are potent, broad spectrum antibiotics which demonstrate potential as novel therapeutic agents. Antimicrobial peptides have been demonstrated to kill Gram negative and Gram positive bacteria, enveloped viruses, fungi and even transformed or cancerous cells. Unlike the majority of conventional antibiotics it appears that antimicrobial peptides frequently destabilize biological membranes, can form transmembrane channels, and may also have the ability to enhance immunity by functioning as immunomodulators.

The major players in the industry are AnaSpec, AMP Biotech, Phoenix Biotech and Novabiotics, with revenues of about 7%, 9%, 3% and about 26% respectively in 2019.

By region, North America had the highest share of sales, at about 35%.

Read the full market overview

This report provides an overview of the global Antimicrobial Peptides market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antimicrobial Peptides and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antimicrobial Peptides sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antimicrobial Peptides market size, projected growth trends, production technologies, key applications, and end-use industries.

Antimicrobial Peptides Segment by Company

AnaSpec

AMP Biotech

Phoenix Biotech

Novabiotics

Chinese Peptide

Ontores

GenScript

Hycult Biotech

Sunsmile

Ruixing Biotechnology

Zhongnong Yingtai Biotechnology

Glam Technology

ProteLight Pharmaceutical & Biotechnology

Antimicrobial Peptides Segment by Type

Plant Antimicrobial Peptides

Microbial Antimicrobial Peptides

Animal Antimicrobial Peptides

Antimicrobial Peptides Segment by Application

Pharmaceuticals

Feed Additives

Others

Antimicrobial Peptides Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antimicrobial Peptides status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antimicrobial Peptides market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antimicrobial Peptides significant trends, drivers, influence factors in global and regions.

6. To analyze Antimicrobial Peptides competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antimicrobial Peptides market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antimicrobial Peptides and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antimicrobial Peptides.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antimicrobial Peptides market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antimicrobial Peptides industry.

Chapter 3: Detailed analysis of Antimicrobial Peptides manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antimicrobial Peptides in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antimicrobial Peptides in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antimicrobial Peptides Industry Trends Table 2. Antimicrobial Peptides Industry Drivers Table 3. Antimicrobial Peptides Industry Opportunities and Challenges Table 4. Antimicrobial Peptides Industry Restraints Table 5. Global Antimicrobial Peptides Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antimicrobial Peptides Revenue Share by Company (2021-2026) Table 7. Global Antimicrobial Peptides Sales Volume by Company (Mg) & (2021-2026) Table 8. Global Antimicrobial Peptides Sales Volume Share by Company (2021-2026) Table 9. Global Antimicrobial Peptides Average Price (US$/Mg) of Company (2021-2026) Table 10. Global Antimicrobial Peptides Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antimicrobial Peptides Key Company Manufacturing Base & Headquarters Table 12. Global Antimicrobial Peptides Company, Product Type & Application Table 13. Global Antimicrobial Peptides Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antimicrobial Peptides by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Plant Antimicrobial Peptides Table 18. Significant Companies of Microbial Antimicrobial Peptides Table 19. Significant Companies of Animal Antimicrobial Peptides Table 20. Global Antimicrobial Peptides Sales Volume by Type 2021 VS 2025 VS 2032 (Mg) Table 21. Global Antimicrobial Peptides Sales Volume by Type (2021-2026) & (Mg) Table 22. Global Antimicrobial Peptides Sales Volume by Type (2027-2032) & (Mg) Table 23. Global Antimicrobial Peptides Sales Volume Share by Type (2021-2026) Table 24. Global Antimicrobial Peptides Sales Volume Share by Type (2027-2032) Table 25. Global Antimicrobial Peptides Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Antimicrobial Peptides Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Antimicrobial Peptides Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Antimicrobial Peptides Sales Value Share by Type (2021-2026) Table 29. Global Antimicrobial Peptides Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Pharmaceuticals Table 31. Significant Companies of Feed Additives Table 32. Significant Companies of Others Table 33. Global Antimicrobial Peptides Sales Volume by Application 2021 VS 2025 VS 2032 (Mg) Table 34. Global Antimicrobial Peptides Sales Volume by Application (2021-2026) & (Mg) Table 35. Global Antimicrobial Peptides Sales Volume by Application (2027-2032) & (Mg) Table 36. Global Antimicrobial Peptides Sales Volume Share by Application (2021-2026) Table 37. Global Antimicrobial Peptides Sales Volume Share by Application (2027-2032) Table 38. Global Antimicrobial Peptides Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Antimicrobial Peptides Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Antimicrobial Peptides Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Antimicrobial Peptides Sales Value Share by Application (2021-2026) Table 42. Global Antimicrobial Peptides Sales Value Share by Application (2027-2032) Table 43. Global Antimicrobial Peptides Sales by Region: 2021 VS 2025 VS 2032 (Mg) Table 44. Global Antimicrobial Peptides Sales by Region (2021-2026) & (Mg) Table 45. Global Antimicrobial Peptides Sales Market Share by Region (2021-2026) Table 46. Global Antimicrobial Peptides Sales by Region (2027-2032) & (Mg) Table 47. Global Antimicrobial Peptides Sales Market Share by Region (2027-2032) Table 48. Global Antimicrobial Peptides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Antimicrobial Peptides Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Antimicrobial Peptides Sales Value Share by Region (2021-2026) Table 51. Global Antimicrobial Peptides Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Antimicrobial Peptides Sales Value Share by Region (2027-2032) Table 53. Global Antimicrobial Peptides Market Average Price (US$/Mg) by Region (2021-2026) Table 54. Global Antimicrobial Peptides Market Average Price (US$/Mg) by Region (2027-2032) Table 55. Global Antimicrobial Peptides Sales by Country: 2021 VS 2025 VS 2032 (Mg) Table 56. Global Antimicrobial Peptides Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Antimicrobial Peptides Sales by Country (2021-2026) & (Mg) Table 58. Global Antimicrobial Peptides Sales Market Share by Country (2021-2026) Table 59. Global Antimicrobial Peptides Sales by Country (2027-2032) & (Mg) Table 60. Global Antimicrobial Peptides Sales Market Share by Country (2027-2032) Table 61. Global Antimicrobial Peptides Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Antimicrobial Peptides Sales Value Market Share by Country (2021-2026) Table 63. Global Antimicrobial Peptides Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Antimicrobial Peptides Sales Value Market Share by Country (2027-2032) Table 65. AnaSpec Company Information Table 66. AnaSpec Business Overview Table 67. AnaSpec Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 68. AnaSpec Antimicrobial Peptides Product Portfolio Table 69. AnaSpec Recent Development Table 70. AMP Biotech Company Information Table 71. AMP Biotech Business Overview Table 72. AMP Biotech Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 73. AMP Biotech Antimicrobial Peptides Product Portfolio Table 74. AMP Biotech Recent Development Table 75. Phoenix Biotech Company Information Table 76. Phoenix Biotech Business Overview Table 77. Phoenix Biotech Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 78. Phoenix Biotech Antimicrobial Peptides Product Portfolio Table 79. Phoenix Biotech Recent Development Table 80. Novabiotics Company Information Table 81. Novabiotics Business Overview Table 82. Novabiotics Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 83. Novabiotics Antimicrobial Peptides Product Portfolio Table 84. Novabiotics Recent Development Table 85. Chinese Peptide Company Information Table 86. Chinese Peptide Business Overview Table 87. Chinese Peptide Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 88. Chinese Peptide Antimicrobial Peptides Product Portfolio Table 89. Chinese Peptide Recent Development Table 90. Ontores Company Information Table 91. Ontores Business Overview Table 92. Ontores Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 93. Ontores Antimicrobial Peptides Product Portfolio Table 94. Ontores Recent Development Table 95. GenScript Company Information Table 96. GenScript Business Overview Table 97. GenScript Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 98. GenScript Antimicrobial Peptides Product Portfolio Table 99. GenScript Recent Development Table 100. Hycult Biotech Company Information Table 101. Hycult Biotech Business Overview Table 102. Hycult Biotech Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 103. Hycult Biotech Antimicrobial Peptides Product Portfolio Table 104. Hycult Biotech Recent Development Table 105. Sunsmile Company Information Table 106. Sunsmile Business Overview Table 107. Sunsmile Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 108. Sunsmile Antimicrobial Peptides Product Portfolio Table 109. Sunsmile Recent Development Table 110. Ruixing Biotechnology Company Information Table 111. Ruixing Biotechnology Business Overview Table 112. Ruixing Biotechnology Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 113. Ruixing Biotechnology Antimicrobial Peptides Product Portfolio Table 114. Ruixing Biotechnology Recent Development Table 115. Zhongnong Yingtai Biotechnology Company Information Table 116. Zhongnong Yingtai Biotechnology Business Overview Table 117. Zhongnong Yingtai Biotechnology Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 118. Zhongnong Yingtai Biotechnology Antimicrobial Peptides Product Portfolio Table 119. Zhongnong Yingtai Biotechnology Recent Development Table 120. Glam Technology Company Information Table 121. Glam Technology Business Overview Table 122. Glam Technology Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 123. Glam Technology Antimicrobial Peptides Product Portfolio Table 124. Glam Technology Recent Development Table 125. ProteLight Pharmaceutical & Biotechnology Company Information Table 126. ProteLight Pharmaceutical & Biotechnology Business Overview Table 127. ProteLight Pharmaceutical & Biotechnology Antimicrobial Peptides Sales (Mg), Value (US$ Million), Price (US$/Mg) and Gross Margin (2021-2026) Table 128. ProteLight Pharmaceutical & Biotechnology Antimicrobial Peptides Product Portfolio Table 129. ProteLight Pharmaceutical & Biotechnology Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Antimicrobial Peptides Distributors List Table 133. Antimicrobial Peptides Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Antimicrobial Peptides Product Image Figure 2. Global Antimicrobial Peptides Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antimicrobial Peptides Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antimicrobial Peptides Sales (2021-2032) & (Mg) Figure 5. Global Antimicrobial Peptides Sales Average Price (US$/Mg) & (2021-2032) Figure 6. Global Antimicrobial Peptides Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Plant Antimicrobial Peptides Image Figure 10. Microbial Antimicrobial Peptides Image Figure 11. Animal Antimicrobial Peptides Image Figure 12. Global Antimicrobial Peptides Sales Volume by Type (2021 VS 2025 VS 2032) & (Mg) Figure 13. Global Antimicrobial Peptides Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Antimicrobial Peptides Sales Volume Share by Type (2021-2032) Figure 15. Global Antimicrobial Peptides Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Antimicrobial Peptides Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Antimicrobial Peptides Sales Value Share by Type (2021-2032) Figure 18. Pharmaceuticals Image Figure 19. Feed Additives Image Figure 20. Others Image Figure 21. Global Antimicrobial Peptides Sales Volume by Application (2021 VS 2025 VS 2032) & (Mg) Figure 22. Global Antimicrobial Peptides Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Antimicrobial Peptides Sales Volume Share by Application (2021-2032) Figure 24. Global Antimicrobial Peptides Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Antimicrobial Peptides Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Antimicrobial Peptides Sales Value Share by Application (2021-2032) Figure 27. Global Antimicrobial Peptides Sales by Region: 2021 VS 2025 VS 2032 (Mg) Figure 28. Global Antimicrobial Peptides Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Antimicrobial Peptides Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Antimicrobial Peptides Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Antimicrobial Peptides Sales Value (2021-2032) & (US$ Million) Figure 32. North America Antimicrobial Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Antimicrobial Peptides Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Antimicrobial Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Antimicrobial Peptides Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Antimicrobial Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Antimicrobial Peptides Sales Value (2021-2032) & (US$ Million) Figure 38. South America Antimicrobial Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Antimicrobial Peptides Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Antimicrobial Peptides Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Antimicrobial Peptides Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Antimicrobial Peptides Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Antimicrobial Peptides Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Plant Antimicrobial Peptides
  • Microbial Antimicrobial Peptides
  • Animal Antimicrobial Peptides
Applications
  • Pharmaceuticals
  • Feed Additives
  • Others
Companies covered
  • AnaSpec
  • AMP Biotech
  • Phoenix Biotech
  • Novabiotics
  • Chinese Peptide
  • Ontores
  • GenScript
  • Hycult Biotech
  • Sunsmile
  • Ruixing Biotechnology
  • Zhongnong Yingtai Biotechnology
  • Glam Technology
  • ProteLight Pharmaceutical & Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antimicrobial Peptides Sales Value (2021-2032)
  4. 1.2.2 Global Antimicrobial Peptides Sales Volume (2021-2032)
  5. 1.2.3 Global Antimicrobial Peptides Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antimicrobial Peptides Market Dynamics
  1. 2.1 Antimicrobial Peptides Industry Trends
  2. 2.2 Antimicrobial Peptides Industry Drivers
  3. 2.3 Antimicrobial Peptides Industry Opportunities and Challenges
  4. 2.4 Antimicrobial Peptides Industry Restraints
3 Antimicrobial Peptides Market by Company
  1. 3.1 Global Antimicrobial Peptides Company Revenue Ranking in 2025
  2. 3.2 Global Antimicrobial Peptides Revenue by Company (2021-2026)
  3. 3.3 Global Antimicrobial Peptides Sales Volume by Company (2021-2026)
  4. 3.4 Global Antimicrobial Peptides Average Price by Company (2021-2026)
  5. 3.5 Global Antimicrobial Peptides Company Ranking (2024-2026)
  6. 3.6 Global Antimicrobial Peptides Company Manufacturing Base and Headquarters
  7. 3.7 Global Antimicrobial Peptides Company Product Type and Application
  8. 3.8 Global Antimicrobial Peptides Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antimicrobial Peptides Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antimicrobial Peptides Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antimicrobial Peptides Market by Type
  1. 4.1 Antimicrobial Peptides Type Introduction
  2. 4.1.1 Plant Antimicrobial Peptides
  3. 4.1.2 Microbial Antimicrobial Peptides
  4. 4.1.3 Animal Antimicrobial Peptides
  5. 4.2 Global Antimicrobial Peptides Sales Volume by Type
  6. 4.2.1 Global Antimicrobial Peptides Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antimicrobial Peptides Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Antimicrobial Peptides Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Antimicrobial Peptides Sales Value by Type
  10. 4.3.1 Global Antimicrobial Peptides Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antimicrobial Peptides Sales Value by Type (2021-2032)
  12. 4.3.3 Global Antimicrobial Peptides Sales Value Share by Type (2021-2032)
5 Antimicrobial Peptides Market by Application
  1. 5.1 Antimicrobial Peptides Application Introduction
  2. 5.1.1 Pharmaceuticals
  3. 5.1.2 Feed Additives
  4. 5.1.3 Others
  5. 5.2 Global Antimicrobial Peptides Sales Volume by Application
  6. 5.2.1 Global Antimicrobial Peptides Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antimicrobial Peptides Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Antimicrobial Peptides Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Antimicrobial Peptides Sales Value by Application
  10. 5.3.1 Global Antimicrobial Peptides Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antimicrobial Peptides Sales Value by Application (2021-2032)
  12. 5.3.3 Global Antimicrobial Peptides Sales Value Share by Application (2021-2032)
6 Antimicrobial Peptides Regional Sales and Value Analysis
  1. 6.1 Global Antimicrobial Peptides Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antimicrobial Peptides Sales by Region (2021-2032)
  3. 6.2.1 Global Antimicrobial Peptides Sales by Region: 2021-2026
  4. 6.2.2 Global Antimicrobial Peptides Sales by Region (2027-2032)
  5. 6.3 Global Antimicrobial Peptides Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antimicrobial Peptides Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antimicrobial Peptides Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antimicrobial Peptides Sales Value by Region (2027-2032)
  9. 6.5 Global Antimicrobial Peptides Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antimicrobial Peptides Sales Value (2021-2032)
  12. 6.6.2 North America Antimicrobial Peptides Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antimicrobial Peptides Sales Value (2021-2032)
  15. 6.7.2 Europe Antimicrobial Peptides Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antimicrobial Peptides Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antimicrobial Peptides Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antimicrobial Peptides Sales Value (2021-2032)
  21. 6.9.2 South America Antimicrobial Peptides Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antimicrobial Peptides Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antimicrobial Peptides Sales Value Share by Country, 2025 VS 2032
7 Antimicrobial Peptides Country-level Sales and Value Analysis
  1. 7.1 Global Antimicrobial Peptides Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antimicrobial Peptides Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antimicrobial Peptides Sales by Country (2021-2032)
  4. 7.3.1 Global Antimicrobial Peptides Sales by Country (2021-2026)
  5. 7.3.2 Global Antimicrobial Peptides Sales by Country (2027-2032)
  6. 7.4 Global Antimicrobial Peptides Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antimicrobial Peptides Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antimicrobial Peptides Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antimicrobial Peptides Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antimicrobial Peptides Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antimicrobial Peptides Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AnaSpec
  2. 8.1.1 AnaSpec Company Information
  3. 8.1.2 AnaSpec Business Overview
  4. 8.1.3 AnaSpec Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AnaSpec Antimicrobial Peptides Product Portfolio
  6. 8.1.5 AnaSpec Recent Developments
  7. 8.2 AMP Biotech
  8. 8.2.1 AMP Biotech Company Information
  9. 8.2.2 AMP Biotech Business Overview
  10. 8.2.3 AMP Biotech Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AMP Biotech Antimicrobial Peptides Product Portfolio
  12. 8.2.5 AMP Biotech Recent Developments
  13. 8.3 Phoenix Biotech
  14. 8.3.1 Phoenix Biotech Company Information
  15. 8.3.2 Phoenix Biotech Business Overview
  16. 8.3.3 Phoenix Biotech Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Phoenix Biotech Antimicrobial Peptides Product Portfolio
  18. 8.3.5 Phoenix Biotech Recent Developments
  19. 8.4 Novabiotics
  20. 8.4.1 Novabiotics Company Information
  21. 8.4.2 Novabiotics Business Overview
  22. 8.4.3 Novabiotics Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novabiotics Antimicrobial Peptides Product Portfolio
  24. 8.4.5 Novabiotics Recent Developments
  25. 8.5 Chinese Peptide
  26. 8.5.1 Chinese Peptide Company Information
  27. 8.5.2 Chinese Peptide Business Overview
  28. 8.5.3 Chinese Peptide Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Chinese Peptide Antimicrobial Peptides Product Portfolio
  30. 8.5.5 Chinese Peptide Recent Developments
  31. 8.6 Ontores
  32. 8.6.1 Ontores Company Information
  33. 8.6.2 Ontores Business Overview
  34. 8.6.3 Ontores Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ontores Antimicrobial Peptides Product Portfolio
  36. 8.6.5 Ontores Recent Developments
  37. 8.7 GenScript
  38. 8.7.1 GenScript Company Information
  39. 8.7.2 GenScript Business Overview
  40. 8.7.3 GenScript Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GenScript Antimicrobial Peptides Product Portfolio
  42. 8.7.5 GenScript Recent Developments
  43. 8.8 Hycult Biotech
  44. 8.8.1 Hycult Biotech Company Information
  45. 8.8.2 Hycult Biotech Business Overview
  46. 8.8.3 Hycult Biotech Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hycult Biotech Antimicrobial Peptides Product Portfolio
  48. 8.8.5 Hycult Biotech Recent Developments
  49. 8.9 Sunsmile
  50. 8.9.1 Sunsmile Company Information
  51. 8.9.2 Sunsmile Business Overview
  52. 8.9.3 Sunsmile Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sunsmile Antimicrobial Peptides Product Portfolio
  54. 8.9.5 Sunsmile Recent Developments
  55. 8.10 Ruixing Biotechnology
  56. 8.10.1 Ruixing Biotechnology Company Information
  57. 8.10.2 Ruixing Biotechnology Business Overview
  58. 8.10.3 Ruixing Biotechnology Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Ruixing Biotechnology Antimicrobial Peptides Product Portfolio
  60. 8.10.5 Ruixing Biotechnology Recent Developments
  61. 8.11 Zhongnong Yingtai Biotechnology
  62. 8.11.1 Zhongnong Yingtai Biotechnology Company Information
  63. 8.11.2 Zhongnong Yingtai Biotechnology Business Overview
  64. 8.11.3 Zhongnong Yingtai Biotechnology Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Zhongnong Yingtai Biotechnology Antimicrobial Peptides Product Portfolio
  66. 8.11.5 Zhongnong Yingtai Biotechnology Recent Developments
  67. 8.12 Glam Technology
  68. 8.12.1 Glam Technology Company Information
  69. 8.12.2 Glam Technology Business Overview
  70. 8.12.3 Glam Technology Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Glam Technology Antimicrobial Peptides Product Portfolio
  72. 8.12.5 Glam Technology Recent Developments
  73. 8.13 ProteLight Pharmaceutical & Biotechnology
  74. 8.13.1 ProteLight Pharmaceutical & Biotechnology Company Information
  75. 8.13.2 ProteLight Pharmaceutical & Biotechnology Business Overview
  76. 8.13.3 ProteLight Pharmaceutical & Biotechnology Antimicrobial Peptides Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 ProteLight Pharmaceutical & Biotechnology Antimicrobial Peptides Product Portfolio
  78. 8.13.5 ProteLight Pharmaceutical & Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antimicrobial Peptides Value Chain Analysis
  2. 9.1.1 Antimicrobial Peptides Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antimicrobial Peptides Sales Mode & Process
  6. 9.2 Antimicrobial Peptides Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antimicrobial Peptides Distributors
  9. 9.2.3 Antimicrobial Peptides Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst